ICER Will Explore Value Pricing For Cures In Context Of ‘Shared’ Health System Savings
Future value assessments will include ‘hypothetical’ scenarios in which downstream medical savings will be shared between the health care system and the treatment developer.
You may also be interested in...
Drug makers have sought a larger role for RWE in ICER's review process; proposed update also includes process to re-evaluate cost-effectiveness evidence after one year.
Public statements by Novartis and AveXis suggest Zolgensma could be cost effective at a price up to $5m. Analysts expect $2m. The lower estimate is still stunning, but could it be considered reasonable by comparison?
Current drug classification standard was originally designed for the Medicare Part D program, which does not cover obesity drugs.